Fat-Soluble Active Ingredient Formulation with Protective Colloid
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of fat-soluble active ingredients face challenges in achieving high bioavailability and stability, particularly due to extrusion loss during tablet formation, which affects shelf life and bioavailability in pharmaceutical applications.
Innovation Solution
A composition of a fat-soluble active ingredient combined with a protective colloid, characterized by a high extinction coefficient when dissolved in water, and a process to minimize extrusion loss, resulting in a formulation with enhanced bioavailability and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fat-soluble active ingredient is incorporated into tablets, then bioavailability is improved, but extrusion loss occurs during tablet formation reducing stability and shelf life
Solution Approach 1:
A protective colloid is introduced as an intermediary substance between the fat-soluble active ingredient and the tablet matrix. This protective colloid forms a stable dispersion that prevents the active ingredient from being extruded during tablet formation, thereby eliminating extrusion loss while maintaining bioavailability. The protective colloid acts as a mediator that protects the active ingredient from harmful interactions with the tablet formulation components.
2Stability of the object's composition
If amount of fat-soluble active ingredient is increased to compensate for extrusion loss, then stability is maintained, but bioavailability efficiency decreases
Solution Approach 1:
The protective colloid provides a feedback mechanism by forming a stable dispersion that continuously protects the active ingredient from extrusion. This stable dispersion maintains consistent levels of active ingredient throughout the tablet's shelf life, eliminating the need to overcompensate with higher initial amounts. The feedback loop ensures that the active ingredient remains protected and bioavailable without requiring excessive quantities.
3Duration of action of stationary object
If protective colloid is used to prevent extrusion loss, then stability and shelf life are improved, but formulation complexity increases
Solution Approach 1:
The protective colloid changes the physical-chemical parameters of the formulation by creating a stable dispersion system. This dispersion has specific rheological properties that prevent extrusion while maintaining simplicity in the overall formulation approach. The parameter changes in the protective colloid's structure and behavior enable it to provide long-term stability without requiring complex multi-component systems or sophisticated formulation strategies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves high bioavailability with reduced extrusion loss, leading to improved stability and extended shelf life of fat-soluble active ingredients in pharmaceutical tablets, and is suitable for use in dietary supplements, food, feed, and personal care products.
Implementation Method 1
a protective colloid characterized in that said composition when dissolved, dispersed or diluted in/with water has an extinction E1/1
Implementation Method 2
measuring the absorption of the solution, and o calculation of the percentage of the total amount of the fat-soluble active ingredient pressed out
Data Source
AI summary
The present invention relates to formulations of a pharmacological effective fat-soluble active ingredient with a high bioavailability of said fat-soluble active ingredient as well as to their manufacture and use as dietary supplement, food, feed, personal care product and/or pharmaceutical. Such formulations are those which when dissolved, dispersed or diluted in/with water have an extinction E 1/1 at a wavelength in the range of from 200 to 800 nm, preferably in the range of from 250 to 600 nm, more preferably in the range of from 250 to 500 nm, more preferably in the range of from 370 to 485 nm, of = 380, preferably of = 600, most preferably = 900. In preferred embodiments of the formulations of the present invention such formulations show an extrusion loss of fat-soluble active ingredient of = 30% when pressed to tablets.